Why use one sentence when several more can be used in it's place?

A few years ago whilst employed with an organisation that shall remain nameless I used to dread the habitual Friday afternoon meeting. I kid you not, it used to last two or three hours and I'm pretty sure I must have nodded off to sleep on more than one occasion (hopefully discreetly and unnoticed). One of the reasons that the meetings were so long was because a key contributor just loved the sound of his own voice. Even worse he would try and construct sentences that were so obtuse they were almost impossible to decipher. I think he was probably trying to create an image of himself as an intellectual and/or deep thinker. However, when you did eventually decipher what he had actually said, it amounted to sod all. I think he might have ended up at Blinkx under an assumed name (just joking). From today's half-yearly report:-

"The Company's mission is to democratize access to quality digital content in a way that is respectful of consumer choice, impactful for the advertiser and sustainable for the content owner. Solving this fundamental equation is critical in order for the industry to thrive. These basic tenets will guide blinkx's decision-making in the near- and long-term, and represent a path to sustainable growth for both the Company and industry."

 

In short, he might have written, "We want to return to profitability, but at the moment we're totally f***ing clueless" 

 

Perhaps that's a little bit harsh, but after recording a whopping $79,000,000 loss they clearly have some work to do.

 

In fairness, I don't know much about Blinkx and can only assume that something in today's statement is propping up the share price. At a glance the company does appear to boast a strong balance sheet.

 

Anyway, it's not one I wish to research and I'll leave this one to the bulls and bears who have done their due diligence.

 

In other news, Angle released another encouraging RNS this morning regarding progress with the commercialisation of it's Parsortix device.

 

http://www.londonstockexchange.com/exchange/news/market-news/market-news-detail/12584389.html

 

For Parsortix to be successful, verification of it's utility from organisations such as Cancer Research UK Manchester Institute are absolutely critical. I am encouraged by the build up of evidence that has now been received from a number of prestigious institutions including tests involving a variety of cancers. Today's report focussed on Lung Cancer, the most common cancer in the world.

 

Key points for me from today's release are as follows:-

 

"ANGLE's Parsortix system "… offers a unique combination of features making it suitable for routine clinical analysis of patient blood samples" "

 

"Ged Brady, Deputy and Genomics Leader within the Clinical & Experimental Pharmacology group at Cancer Research UK Manchester Institute, commented:

"The Parsortix system has a unique combination of features making it suitable for routine clinical analysis of patient blood samples.  We have now incorporated the Parsortix workflow into multiple clinical trials and have been accumulating many hundreds of stored enriched samples that will be of immense value in our future CTC studies."  "

 

"ANGLE's Founder and Chief Executive, Andrew Newland, added:

"This is our second peer-reviewed publication in a scientific journal and adds to the growing body of published evidence of Parsortix's performance as a liquid biopsy.  The success in pilot studies in harvesting CTCs from 100% of small-cell lung cancer patients comes after similar performance with 100% of prostate, breast and ovarian cancer types.  We believe Parsortix is changing the paradigm for CTC capture and harvest for liquid biopsy and will change CTC molecular analysis from being a theoretical but impractical goal to being simple and effective in hospital laboratories all over the world.  The prospect of deployment of our repeatable, non-invasive liquid biopsy in the treatment of lung cancer patients is exciting and has the potential to make a major impact in improving future cancer care."  "

 

Still a speculative investment until sales begin to arrive of course, but critically the experts are impressed and so far they have all verified Parsortix's potential and utility. I await further news with interest.